1. Introduction {#sec1}
===============

In the early part of the twentieth century the work of Seitelberger ([@bib11; @bib30]) and others described the clinicopathological features of the 2 commonest forms of neurodegeneration with iron deposition, that is neuroaxonal dystrophy (NAD) and Hallervorden-Spatz disease, now renamed neurodegeneration with brain iron accumulation (NBIA) ([@bib7]).

The 2 major types of NBIA are recessively inherited disorders, NBIA type 1 is due to mutations in the pantothenate kinase 2 gene (*PANK2*) and often called pantothenate kinase associated neurodegeneration (PKAN) ([@bib15; @bib36]) and NBIA type 2 or infantile neuroaxonal dystrophy (INAD) (previously Seitelberger\'s disease) is due to mutations in the phospholipase A2, group VI (*PLA2G6*) gene ([@bib18; @bib22; @bib30]). According to the age of onset and progression, NAD can be separated into: (1) infantile or classical type (INAD), and (2) juvenile/adult onset or atypical NAD. A further group comprises idiopathic NBIA where there is brain iron on imaging but no genetic abnormality in the *PLA2G6* and *PANK2* genes ([@bib7; @bib22]). Two other genes also cause NBIA, acoeruloplasminaemia due to mutations in the (ceruloplasmin) *CP* gene ([@bib23]) and neuroferritinopathy, caused by mutations in the *FTL* (ferritin light polypeptide) gene. Patients with mutation of these 2 genes usually present with an adult onset movement disorder ([@bib4]). The vast majority of PKAN cases have imaging evidence of high iron accumulation but this is only present in half the cases with *PLA2G6* mutations. PKAN accounts for approximately 50% of the cases with NBIA ([@bib14; @bib18; @bib22]). Recently families with adult onset dystonia-parkinsonism were found to have mutations in the *PLA2G6* gene but absent iron deposition on magnetic resonance imaging (MRI) ([@bib28; @bib31]).

The clinical phenotype of NBIA is broad, although there are some characteristic features ([@bib7; @bib15]). Most cases present before the age of 5 years with developmental delay, dystonia, rigidity, dysarthria, and ataxia. Onset between 2 and 18 years is characteristic for the juvenile type and onset after 18 years for the adult type or atypical NAD. The finding of patients with *PLA2G6* mutations and L-dopa responsive adult onset dystonia-parkinsonism adds a later onset subgroup to the NBIA clinical spectrum. MRI has been of great importance in distinguishing the clinical and genetic forms of NBIA. In cases with PKAN mutations a region of hyperintensity (necrosis or edema) in the globus pallidus is seen with surrounding hypodensity (region of high iron) on T2-weighted images ([@bib14]). This "eye of the tiger" sign is associated with mutations in the *PANK2* gene ([@bib1; @bib2; @bib6; @bib9; @bib10; @bib13; @bib16]) but is not pathognomonic ([@bib21]). In classical INAD, abnormal iron mainly accumulates in the globus pallidus and sometimes in the substantia nigra in the more atypical cases ([@bib7; @bib15]).

In the past it has been possible to differentiate NAD from PKAN pathologically mainly by the distribution of dystrophic neuroaxonal swellings (spheroids). These have been shown by immunohistochemistry to be immunoreactive for neurofilament, amyloid precursor protein, ubiquitin, and alpha-synuclein ([@bib1; @bib6; @bib7; @bib25; @bib26; @bib27; @bib29; @bib32; @bib33; @bib34; @bib35]), although larger spheroids may be negative for neurofilament. However, with identification of the *PLA2G6* gene, it has become clear that there is also pathological heterogeneity in NAD, as cases with clinical and pathological features of INAD were found to be negative for *PLA2G6* mutations and patients with *PLA2G6* mutations have been identified without axonal spheroids ([@bib7]). The neuropathological examination of only 1 case with a confirmed *PLA2G6* mutation has been reported in a patient with atypical neuroaxonal dystrophy and an age of onset of 3 years. This case had typical axonal spheroids, iron deposition, Lewy bodies, and Lewy neurites in the substantia nigra and cortex as well as tau immunoreactive tangles ([@bib7]).

To expand the neuropathological spectrum of neuroaxonal dystrophy caused by *PLA2G6* mutations and investigate the overlap with other parkinsonian disorders, we identified 7 genetically-proven cases with infantile through to adult onset disease and report the clinical and neuropathological features.

2. Methods {#sec2}
==========

This project was approved by the Joint Local Research Ethics Committee of the National Hospital for Neurology and Neurosurgery. Brains are stored in the Queen Square Brain Bank, London (QSBB) and the Brain and Tissue Banks for Developmental Disorders, Baltimore (BTBDD) by obtaining appropriate consents.

2.1. Patients {#sec2.1}
-------------

The clinical features of the patients examined are described in the results section and [Table 1](#tbl1){ref-type="table"}. Cases 1 and 2 were from the QSBB. Cases 3--6 were from the National Institute of Child Health and Human Development (NICHD), Brain and Tissue Bank for Developmental Disorder. Tissue from these disorders is rare as brain donation is not frequently made by families; we contacted as many brain banks as possible to obtain tissue from cases with a young onset complex dystonia or parkinsonian disorder. In cases 1, 2, and 4 detailed clinical notes were available, clinical details in cases 3 and 5 were minimal. Cases 1, 3, 4, and 5 underwent detailed neuropathological examination. Tissue from a cortical biopsy was available in case 2. The neuropathological findings of case 2 ([@bib33]) and case 5 ([@bib6]) had been reported earlier. Two further cases (case 6 and 7) only had a sural nerve biopsy carried out.

2.2. Genetics {#sec2.2}
-------------

DNA was extracted from brain tissue or blood using a standard phenol chloroform method. All exons of the *PANK2* gene were sequenced as was exon 4 of the ferritin light chain gene (the only exon shown to have mutations) ([@bib4]) as both genes have an NBIA phenotype and were found to be negative.

All 16 coding exons of the *PLA2G6* gene (reference sequence [NM_003560](ncbi-n:NM_003560)) were sequenced, as with the other genes given above, using standard Sanger PCR sequencing (Roche Faststart Mastermix, Roche, Indianapolis), purification (Millipore, Billerica, MA), Bigdye (ABI/Perkin Elmer, Waltham, MA) sequencing reaction, Bigdye clean up (ABgene, Epsom, UK) and running on an ABI3730XL sequencer. Primers were designed to amplify each gene exon and flanking 50 bp intronic sequences ([Table 1](#tbl1){ref-type="table"}). The controls screened were from the UK Wellcome trust 1958 birth cohort and the *Centre d\'Etude du Polymorphisme Humain* (CEPH) Human Genome Diversity Panel (HGDP), these samples are available from the Wellcome trust or CEPH. Mutations were numbered from the ATG start site of the *PLA2G6* gene.

2.3. Neuropathology {#sec2.3}
-------------------

The entire brain was examined in case 1; paraffin blocks from representative brain areas were available from case 4. In case 2 frontal cortical biopsy tissue was available and frozen material was only available from case 3. Seven μm thick tissue sections were stained with hematoxylin and eosin, Luxol fast blue cresyl violet, Perl\'s stain for iron and Gallyas silver methods. Immunohistochemistry was performed with antibodies to glial fibrillary acidic protein (Dako, 1:1000, Ely, UK), alpha-synuclein (Novocastra, 1:50, Newcastle, UK), phospho-alpha-synuclein (Abcam,1:1000, Cambridge, UK), tau (AT8, Autogen Bioclear, 1:500, Nottingham, UK), AT100, Autogen Bioclear 1:200, Nottingham, UK), ubiquitin (Dako, 1:200, Ely, UK), p62 (BD Transduction, 1:100, Oxford, UK, neurofilament (RT97 Novocastra, 1:50, Newcastle, UK), SMI31 Sternberger Monoclonals, 1:5000, Cambridge, UK), anti-mouse or anti-rabbit secondary antibody (Dako, Ely, UK) was used as appropriate, followed by incubation with ABC (Vector, Peterborough, UK). Color was developed by diaminobenzidine/H~2~O~2~. Sections were counterstained with Mayer\'s hematoxylin.

3. Results {#sec3}
==========

Clinical details are summarized in [Table 2](#tbl2){ref-type="table"}. Cases 1 and 2 were from the host brain bank where complete clinical details were available, cases 3--7 were from another brain bank where copies of the clinical notes were obtained but these cases had not been seen by any of the coauthors. Cases 3, 5, 6, and 7 all had the typical clinical features of classical NAD with psychomotor regression at around 1 year of age and progressive loss of ambulation before aged 5 years. All cases had progressive cognitive and developmental deterioration, with ataxia, speech, and swallowing problems. Visual problems occurred in case 3 (bilateral optic atrophy) and case 6, bilateral hearing loss, seizures, flaccidity, and muscle cramps in case 5. Imaging demonstrated cerebellar atrophy in all cases and iron accumulation only in case 6 in the basal ganglia region, typical of NAD, although imaging was done early on in the disease in cases 3 and 5. Case 4 had juvenile or atypical NAD with an age of onset in childhood with dystonia and paroxysmal jerky body movements that were consistent with myoclonic jerks; an electroencephalogram (EEG) showed right-sided spike and slow wave discharges. Although this patient improved with feeding and weight gain after a gastrostomy tube was inserted, he continued to globally progress and died aged 18 years. The case of death in all cases was aspiration or ventilation-related pneumonia.

Cases 1 and 2 had a later age of onset, slower disease progression, and both developed parkinsonian features. Although the overall clinical features of these 2 cases were different than idiopathic Parkinson\'s disease (PD) there is overlap and both cases are discussed in detail below and given in [Table 2](#tbl2){ref-type="table"}. Case 1 had a diagnosis of "adult-onset progressive ataxia, spasticity, and parkinsonism". She had no relevant past medical or psychiatric history apart from toe walking. At the age of 18 she had increasing problems with overt urinary incontinence and constipation. She was 28 years old when presented to a neurologist. Her examination revealed normal eye movements, mild cerebellar dysarthria, and ataxia, and mild pyramidal weakness in all limbs. Brain imaging and central and peripheral electrophysiology, cerebrospinal fluid (CSF), and muscle biopsy were all normal. Neuropsychometry suggested mild cognitive decline. These problems progressed, she could no longer work from age 30 and became wheelchair-bound due to increasing ataxia and spasticity at the age of 32 years. She developed psychiatric features with aggression, swallowing difficulties, and dysarthria and a sensory neuropathy. Parkinsonism with rigidity and bradykinesia was first noted at age 34; this involved the upper limbs and affected the gait in a symmetrical pattern. Dystonia was absent. Repeat MRI showed cerebellar atrophy. She further progressed, became bedbound with severe akinetic rigidity, was mute, and unable to communicate. She died of bronchopneumonia at the age of 36.

Case 2 had a diagnosis of an adult-onset progressive dystonia-parkinsonism disorder. She was well until the age of 22 years when she developed psychiatric features with mood changes, irritability, aggression, and transient visual hallucinations. She had a rapidly progressive decline in language abilities and became mute within 9 months. She also had weight loss and feeding problems. She received psychiatric treatment including electroconvulsive therapy and haloperidol, which resulted in extrapyramidal side effects. These improved rapidly with clozapine as did her mood. At the age of 24, her extrapyramidal features returned and she developed progressive tremor, bradykinesia, and micrographia with a shuffling gait and falls. L-dopa therapy was initially successful but later on in the disease course she did not respond and developed limb and orofacial dyskinesias a short time after dosing. On examination at age 28, her higher mental functions were severely impaired on verbal and nonverbal tests of reasoning. She was hypomimic with reduced visual perceptual and visuospatial skills. Pursuit eye movements were jerky, and saccades were slow. She had marked dystonic posturing of all extremities. Her reflexes were brisk and the plantar responses were spontaneously extensor. Brain MRI at age 27 years showed severe cerebral, predominantly frontotemporal atrophy. Low signal intensity, indicative of abnormal iron deposition in the globus pallidus, cerebral peduncles, and substantia nigra without "eye of the tiger" sign were present on T2-weighted images. This patient was investigated in detail for other acquired caused of dystonia and parkinsonism; these were normal and included metabolic screening, muscle, rectal biopsy, and bone marrow biopsies, genetic testing for SCA1--3, 6, 7, 12, 17, Huntington disease, dystonia 1 gene (*DYT1*)-related primary dystonia, alpha-synuclein and dentatorubropallidoluysian atrophy (DRPLA). After these investigations proved negative a full thickness right frontal brain biopsy was carried out; these results are discussed below.

3.1. Mutation analysis {#sec3.1}
----------------------

Sequencing of the *PLA2G6* gene revealed the presence of mutations in the examined cases ([Tables 2 and 3](#tbl2 tbl3){ref-type="table"}). Ten different *PLA2G6* mutations were identified and confirmed by repeat sequencing. Six of them, including frameshift, missense, splice site, and stop mutations were novel ([Table 2](#tbl2){ref-type="table"}); conserved in species and not identified in controls. The 2 novel missense mutations, *p*.*R600Q* and *p*.*T572I*, were also not identified in 548 and 380 control chromosomes, respectively, and both were conserved across species. Cases 2 and 6 were homozygous mutations, cases 1, 3, and 5 were compound heterozygous. Cases 4 and 7 had single heterozygous mutations. Case 7 was clinically diagnosed with peripheral nerve pathology. In this case a single heterozygous mutation was identified in the *PLA2G6* gene. In cases 4 and 7 we analyzed the DNA on Human610-Quad-Infinium HD BeadChips to investigate the *PLA2G6* gene for deletions. However, this array platform only contains 14 markers located in exon 2 and introns 1, 2, 3, 4, 5, 8, and 10 at the *PLA2G6* locus; thus, we could have missed a small heterozygous deletion affecting only a small part of the gene. The fact that both mutations are found in heterozygous states also suggests that if there are deletions at the *PLA2G6* locus in these cases, these will not affect the entire locus. Hence, the *PLA2G6* deletions in these cases are expected to be small and thus not appreciable through the single nucleotide polymorphism (SNP) genotyping assays. Case 7 was homozygous for the 14 single nucleotide polymorphisms at the *PLA2G6* locus, suggesting the presence of a small deletion on 1 allele (likely compound heterozygous nonsense mutation/deletion). Case 4 was homozygous in several regions of the gene with a deletion possible of exons 2, 5 to 8, or 10 to 17 ([Supplementary Material](#sec7){ref-type="sec"}). Because of the single heterozygous changes identified in cases 4 and 7 and the lack of absolute proof of a second mutation these 2 cases should be considered only probable *PLA2G6* NBIA.

3.2. Neuropathology {#sec3.2}
-------------------

The neuropathological data are summarized in [Table 4](#tbl4){ref-type="table"}. Gross inspection revealed cerebral atrophy in case 5 and cerebellar cortical atrophy was documented in cases 1 and 5. A rusty discoloration of the globus pallidus was found in case 4. Severe pallor of the substantia nigra was seen in case 1 (age at death 36 years). On microscopic investigation the globus pallidus contained small clusters of iron-laden macrophages in case 1, while the iron deposition was severe in case 4 ([Fig. 1](#fig1){ref-type="fig"}A) and widespread in case 5. There were numerous axonal swellings in case 1, 3, 4, and 5 ([Fig. 1](#fig1){ref-type="fig"}B and C) in the basal ganglia and brainstem. In case 1 and 5 where the spinal cord was available, there were also numerous axonal spheroids in the cord. On hematoxylin and eosin stained histological sections the axonal swellings appeared as large spherical structures, up to 100 μm in diameter and were mostly stained with the antineurofilament antibodies. There was variable depletion of cerebellar cortical neurons (granular cells more than Purkinje cells) accompanied by marked astrocytosis in cases 1, 4, and 5 ([Fig. 1](#fig1){ref-type="fig"}D), in which the cerebellum was available for assessment. The substantia nigra neurons were depleted in case 1. In this case and also in case 4 Lewy bodies were readily found in the nigra on the hematoxylin and eosin- stained sections. Alpha-synuclein positive Lewy bodies were widespread in cases 1, 4 and 5. In case 2, where only the biopsy specimen of the frontal cortex was available, Lewy bodies were frequent. Lewy bodies were restricted to the medulla in case 3, corresponding to Braak stage 1. In cases 1 and 4 the morphological appearances and the topographical distribution of the Lewy body type pathology were comparable to those seen in severe, end-stage Parkinson\'s disease and cases with dementia with Lewy bodies ([@bib12; @bib20]). Accordingly, severe Lewy body pathology was observed in the "dementia with Lewy bodies" consensus areas, including cerebral cortex, basal forebrain, hippocampal formation, and brainstem nuclei corresponding to "diffuse neocortical Lewy body type pathology" ([@bib20]) and Braak stage 6 ([@bib3]) in both case 1 and 4 ([Fig. 2](#fig2){ref-type="fig"}A--E). Lewy bodies and Lewy neurites in nigra and/or cortex were ubiquitin-positive and were confirmed to contain alpha-synuclein phosphorylated at Serine 129. In addition, alpha-synuclein accumulation was observed in axonal swellings in all postmortem cases (cases 1, and 3--5).

There was extensive tau pathology with neurofibrillary tangles, pretangles, and neuropil threads in case 4 corresponding to Braak and Braak stage V ([Fig. 2](#fig2){ref-type="fig"}F). The AT8-positive structures were also AT100-positive and Gallyas silver-positive, which is indicative of tau filaments. Tau-positive threads and neurofibrillary tangles were restricted to the transentorhinal cortex in case 1 (Braak and Braak stage I). There were numerous, tau-positive neuropil threads in case 2 investigated by a frontal cortical biopsy and tau-positive glia in hippocampus and entorhinal cortex were described in case 5 ([@bib6]).

4. Discussion {#sec4}
=============

We describe the genetic and clinical features of a total of 7 cases with NAD associated with *PLA2G6* mutations. An important addition to the literature provided by this study is the neuropathological data on cases with varying ages of onset, including 2 adult onset cases. A wide distribution of missense, nonsense, and frameshift mutations was identified in the *PLA2G6* gene, which were not identified in controls. The clinical features in the classical INAD and juvenile cases were very similar and have been previously well described. Cases 1 and 2 presented later with ages of onset of 18 and 22; they had a slower progression with prominent psychiatric symptoms: rigidity, dystonia, and parkinsonian features. Case 2 responded to L-dopa treatment but was very sensitive, developing the side effects of worsening dystonia and dyskinesias. L-dopa was not prescribed in case 1.

Neuroaxonal dystrophy and alpha-synuclein pathology with Lewy bodies and Lewy neurites was seen in all cases, in which the brain was examined postmortem and severe alpha-synuclein pathology was also confirmed in the case investigated by a cerebral cortical biopsy. Tau pathology was also present in 3 postmortem cases (cases 1, 4, and 5) and the biopsy case (case 2). In cases 1 and 4 the Lewy body pathology was severe in the neocortex and also in the basal forebrain, hippocampal formation, and brainstem nuclei corresponding to Braak stage 6 ([@bib3]) and to "diffuse neocortical Lewy body type pathology" according to the consensus criteria established for the diagnosis of dementia with Lewy bodies ([@bib20]).

In keeping with previous observations ([@bib8]) a striking aspect of our cohort of NBIA type 2 cases with *PLA2G6* mutations and consisting of young individuals (age at death ranging between 8 and 36 years), is the presence of alpha-synuclein pathology, which was severe in 3 cases and in 2 of the postmortem cases it corresponded to that seen in end stage Parkinson\'s disease and dementia with Lewy bodies ([@bib12; @bib20]). The widespread distribution of Lewy bodies in the brains in our patients may explain the psychiatric features (in cases 1 and 2) and psychomotor retardation in other cases. The Lewy bodies in the cases reported here with L-dopa responsive parkinsonian features and the reported cases with dystonia and parkinsonism clearly represent a link between cases with *PLA2G6* mutations and Parkinson\'s disease. Our observations are also in line with recent reports of PLA2G6 null mice showing accumulation of alpha-synuclein in axonal and cytoplasmic aggregates ([@bib19]).

In 4 of the cases there was also hyperphosphorylated tau accumulation in both neuronal processes (threads) and perikarya (pretangles and neurofibrillary tangles) in cases 1 and 4 and in threads in case 2. The tau pathology was subtle and mostly restricted to the entorhinal cortex in case 1, but was severe in both mediotemporal structures and frontal and temporal neocortex in case 4 corresponding to Braak stage V. In case 2 with disease onset in early adulthood numerous, tau-positive fine threads were present in the frontal cortical biopsy specimen. The co-occurence of hyperphosphorylated tau deposition in these cases is of considerable interest as the young age of the patients excludes an "age-related, incidental" phenomenon and amyloid-β plaques were not seen in any of the cases. Codeposition of tau and alpha-synuclein has been documented in both familial PD ([@bib5]) and sporadic PD ([@bib17; @bib24]). The extent and severity of the tau pathology in some of our cases and in a previously reported case with *PLA2G6* mutation ([@bib8]) also raise the possibility of a mechanistic link not only between *PLA2G6* mutations and alpha-synuclein accumulation, but also between *PLA2G6* mutations and tau hyperphosphorylation and deposition.

The cases reported here all had the neuropathological features of neuroaxonal dystrophy, alpha-synuclein-positive Lewy bodies and Lewy neurites. In all but one case, tau pathology was also present. The clinical features of the cases reported are different. There is a possible genotype phenotype correlation that may explain the differences between the classical INAD (childhood) and the late-onset atypical NAD cases, although the dataset here is small. In the classical INAD cases the mutation distribution occurs throughout the gene with nonsense and frameshift mutations occurring more frequently; these mutations are likely to cause loss of the PLA2G6 functional protein. Atypical cases have a greater number of missense and compound heterozygous mutations toward the 3′ prime end of the gene and this is particularly the case in the 4 families with adult atypical NAD and parkinsonism ([Table 5](#tbl5){ref-type="table"}). Families 1, 2, and the Iranian family were previously reported ([@bib28; @bib31]). The *PLA2G6* mutation position and type may give some indication of the possible phenotype, but this is not comprehensive. Gregory and colleagues recently described similar *PLA2G6* mutations causing a classical INAD phenotype and a codon 741 mutation ([@bib7]).

This report further defines the clinical features and neuropathology of PLA2G6 related NAD. We particularly highlight the role of PLA2G6-related neurodegeneration in patients with juvenile and adult-onset disease complicated by dystonia and parkinsonism with normal MRI imaging. The finding of Lewy body pathology in PLA2G6 bridges a link with other neurodegenerative diseases like Parkinson\'s disease and dementia with Lewy bodies and may shed light on shared pathological pathways.
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![(A) Significant degree of pigment deposition in the globus pallidus in case 4. (B) Empty baskets highlighting significant Purkinje cell loss in the cerebellar cortex in case 1. (C) Large neuroaxonal swellings in the gracile nucleus in case 1, which were often immunoreactive for neurofilament (D). (A and C) Hematoxylin and eosin (H&E); (B and D) phospho-neurofilament immunohistochemistry (pNF) (RT97 antibody). The bar on (A) represents 40 μm.](gr1){#fig1}

![(A and B) Frequent Lewy bodies in substantia nigra neurons in case 1. Severe Lewy pathology is demonstrated in the entorhinal cortex (C), CA2 hippocampal subregion (D), and temporal neocortex (E) in case 1. The tau pathology was extensive in case 3 and demonstrated here in the temporal cortex. (A) Hematoxylin and eosin (H&E); (B--E) alpha-synuclein immunohistochemistry (αSyn); (F) tau immunohistochemistry (AT8 antibody). The bar on (A) represents 80 μm.](gr2){#fig2}

###### 

PCR and sequencing primers used to amplify *PLA2G6*, *PANK2* and *FTL*

             Forward sequence (5′ to 3′)   Reverse sequence (5′ to 3′)
  ---------- ----------------------------- -----------------------------
  *PLA2G6*                                 
   Exon 2    GTGTCTGTGCAGGAAACCG           GCCAATAAGACCTCCAATCC
   Exon 3    TGATTCCAGCAGGGATGTG           AACTATGGAGGGGAACCGAG
   Exon 4    AAAGTCCGAGTTTCCGAGTG          AGGCCTGAGAGTGACACCTG
   Exon 5    GTGATCCACCCACCTTGG            TGGTGGATACTGCTTGCCTC
   Exon 6    CTTCATCCCACGCCACG             GAACCTGCTTCCTGAGGG
   Exon 7    TCAGAGCAGAAGTGGCAGTG          GGGAGGAGGGCTCCAGTC
   Exon 8    CTGGGTGAGTTGACAGGTTG          ACTTCCCTCCTCCTCGGTC
   Exon 9    AGTGTGGAAAGGAGGGGC            GATCCTGTTGCTTTGGTGG
   Exon 10   CTAGGGACCTCTGGGGTAGC          GTGAGGGGCAGGAAAGC
   Exon 11   ACAAGGGCTATGAGGGTGG           GCAAAGCCCTGAAGACAAAC
   Exon 12   GCTCTGCAGGCTGTTCTACG          CTCAGCAGGACAGGGAGC
   Exon 13   GTGTGAATTGTGGGGAAAGG          GATGGCAAGTGCACGACTC
   Exon 14   CTGAGATCTGGAGTGCATGG          GTCCCTAGCATGGTTTGCTG
   Exon 15   CCCCAGAGCCCAGTCTTG            AGGATGAGGGGAAGCCATC
   Exon 16   CTGACTCGAAAGAGCCTGG           GGGAACAGAGCAGACCCTTG
   Exon 17   ACCCTGGTCCTAGCTGGC            GGCAGGGGTACGGTTGTG
  *PANK2*                                  
   Exon 1A   GCTCTATTCCAGAGACCGAGTG        ATTTCCAACTTGAAATCTAACCAG
   Exon 1B   ACCAGCCTGGACAACATAGTG         GACTGGAACAGAATTCAACTGAG
   Exon 2    TTTCAGCACTTAGTTCACTTTAGG      CCAGAACTTCACCAATATAGCAC
   Exon 3    TTATTAAGAGGACTGTGTGGAGTG      CTCATATTCCATGATCTTCCAGAC
   Exon 4    TTTACTTCATGTGATGCCAGG         TCTTAAACAAACCACATTGTCTTC
   Exon 5    GCACTGTACTTCTTCCATGAGG        CAGTCAGATGTCATACTCACCAAG
   Exon 6    TTGTTGTAGATGATGCATACTTGG      AGAGTTTTAGGGACACAGGCAC
   Exon 7    ACTGTTTAATGCAGGACGAATG        GATGACTACTCCAGCACAGACAAC
  *FTL*                                    
   Exon 4    GCCTCATTTCACACCTGTC           CTCCTCTTTCACTGGCATC

Oligonucleotide primers used to amplify the exonic regions and flanking introns of the phospholipase A2, group VI (*PLA2G6*), the pantothenate kinase 2 (*PANK2*) and the ferritin light chain (*FTL*) genes.

Key: PCR, polymerase chain reaction.

###### 

Clinical features in the cases with *PLA2G6* genetic mutations

  Case   Age of onset   Age of death       First clinical symptom        Ataxia                              Dystonia                            Dysphagia                                                        Other
  ------ -------------- ------------------ ----------------------------- ----------------------------------- ----------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------------------------
  1      18 years       36 years           Tripping and prone to falls   [a](#tblfn1){ref-type="table-fn"}   [b](#tblfn2){ref-type="table-fn"}   Late onset dysphagia requiring a gastrostomy at age 28           Rigidity and bradykinesia, emotional and aggressive outbursts, anarthria
  2      22 years       32 years (alive)   Mood changes and aggression   [c](#tblfn3){ref-type="table-fn"}   [a](#tblfn1){ref-type="table-fn"}   [c](#tblfn3){ref-type="table-fn"}                                Dystonia, rigidity and bradykinesia, emotional and aggressive outbursts
  3      Infant         8 years            Developmental delay           Yes                                 [b](#tblfn2){ref-type="table-fn"}   [a](#tblfn1){ref-type="table-fn"}, gastrostomy                   Bilateral optic atrophy. MRI − cerebellar hypoplasia with hypomyelination
  4      Childhood      18 years           Dystonia and myoclonus        NA                                  [d](#tblfn4){ref-type="table-fn"}   [a](#tblfn1){ref-type="table-fn"}, gastrostomy                   EEG right side slowing and spike slow wave discharges
  5      14 months      8 years            Developmental delay           [a](#tblfn1){ref-type="table-fn"}   [b](#tblfn2){ref-type="table-fn"}   [d](#tblfn4){ref-type="table-fn"}                                Hearing loss, seizures, cramps, flaccid tone. CT, EEG normal at 30 months
  6      11 months      12 years (alive)   Psychomotor retardation       [a](#tblfn1){ref-type="table-fn"}   NA                                  [a](#tblfn1){ref-type="table-fn"}, G-tube inserted for feeding   Seizures, hypothermia, bradycardia, tracheostomyMRI shows iron deposition
  7      Infantile      NA                 Developmental delay           NA                                  NA                                  NA                                                               NA

As with the PEG, the G-tube is use if patients require long-term tube feeding.

Key: CT, computerized tomography; EEG, electroencephalogram; G, ; MRI, magnetic resonance imaging; NA, information not available; PEG, ; *PLA2G6*, phospholipase A2, Group VI; Yes, symptom present but no severity given.

Severe symptom.

Symptom not present.

Mild symptom.

Moderate symptom.

###### 

*PLA2G6* gene mutations identified

  Case   Sex   Ethnicity           Mutation                    Amino acid change    Type and location     Diagnosis
  ------ ----- ------------------- --------------------------- -------------------- --------------------- ---------------------
  1      F     British             c.109C\>Tc.1078 -- 3C\>A    p.R37XSplice site    Exon 2Exon 8          Juvenile onset NAD
  2      F     Greek               c.1715C\>T                  p.T572I              Exon 12Homozygous     Adult onset NAD
  3      M     AmericanCaucasian   c.1061T\>Cc.1933C\>T        p.L354Pp.R654X       Exon 7Exon 14         Infantile onset NAD
  4      M     AmericanCaucasian   c.319delC                   p.L107FsX4           Exon 3Heterozygous    Juvenile onset NAD
  5      M     American            c.610 -- 1G\>Tc.2370delTG   Splice sitep.Y790X   Exon 5Exon 17         Infantile onset NAD
  6      M     Hispanic            c.1799G\>A                  p.R600Q              Exon 13Homozygous     Infantile onset NAD
  7      M     Portuguese          c.2370T\>G                  p.Y790X              Exon 17Heterozygous   Infantile onset NAD

Key: AR, autosomal recessive; F, female; M, male; NAD, neuroaxonal dystrophy; *PLA2G6*, phospholipase A2, group VI.

###### 

Pathological features in the cases with *PLA2G6* genetic mutations

  Case                                                            Amino acid change    Cortical atrophy   Cerebellar atrophy   Neuroaxonal spheroids               Lewy body pathology                                                                               Tau pathology
  --------------------------------------------------------------- -------------------- ------------------ -------------------- ----------------------------------- ------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------
  1QSBBBrain and cord                                             p.R37XSplice site    No                 Yes                  [a](#tblfn5){ref-type="table-fn"}   [a](#tblfn5){ref-type="table-fn"}Braak stage 6; "diffuse neocortical Lewy body type pathology"    [b](#tblfn6){ref-type="table-fn"}Neurofibrillary tangles and neuropil threads
  2[c](#tblfn7){ref-type="table-fn"}QSBBFrontal cortical biopsy   p.T572I              N/A                N/A                  [d](#tblfn8){ref-type="table-fn"}   [a](#tblfn5){ref-type="table-fn"}                                                                 [e](#tblfn9){ref-type="table-fn"}Neuropil threads
  3NICHDBrain                                                     p.L354Pp.R654X       N/A                N/A                  [e](#tblfn9){ref-type="table-fn"}   [b](#tblfn6){ref-type="table-fn"}                                                                 Zero
  4NICHDBrain                                                     p.L107FsX4           No                 No                   [a](#tblfn5){ref-type="table-fn"}   [f](#tblfn10){ref-type="table-fn"}Braak stage 6; "diffuse neocortical Lewy body type pathology"   [a](#tblfn5){ref-type="table-fn"}Neurofibrillary tangles and neuropil threads
  5[g](#tblfn11){ref-type="table-fn"}NICHDBrain and cord          Splice sitep.Y790X   Yes                Yes                  Yes                                 Yes[g](#tblfn11){ref-type="table-fn"}                                                             Tau-positive glia[g](#tblfn11){ref-type="table-fn"}
  6[h](#tblfn12){ref-type="table-fn"}NICHDSural nerve only        p.R600Q              N/A                N/A                  Yes                                 N/A                                                                                               N/A
  7[h](#tblfn12){ref-type="table-fn"}No tissue                    p.Y790X              N/A                N/A                  N/A                                 N/A                                                                                               N/A

The sural nerve pathology was from the reporting hospital.

Key: N/A, no information available; No, pathological feature not present; NICHD, case from National Institute of Child Health and Human Development, Brain and Tissue Bank, Baltimore, MD; *PLA2G6*, phospholipase A2, Group VI; QSBB, case from the Queen Square Brain Bank, London, UK; Yes, pathological feature present.

Severity of pathological change severe.

Severity of pathological change mild.

Previously reported, formal assessment was performed in the present study (Tofaris et al., 2007).

Severity of pathological change absent.

Severity of pathological change moderate.

Severity of pathological change very severe.

Previously reported, no formal assessment in the present study as tissue was not available (Galvin et al., 2000).

No brain tissue available.

###### 

Sample of atypical cases with adult atypical NAD and parkinsonism show a greater number of missense and compound heterozygous mutations

  Case             Mutation                   Age of onset (years)   Phenotype               Neuropathology
  ---------------- -------------------------- ---------------------- ----------------------- ---------------------
  Case 1 (here)    p.T572I                    18                     Dystonia-parkinsonism   Lewy bodies and tau
  Case 2 (here)    p\. R37X/c.1078--3C \> A   22                     Dystonia-parkinsonism   Lewy bodies and tau
  Family 1         p.R741Q                    10 and 26              Dystonia-parkinsonism   Not available
  Family 2         p.R747W                    18                     Dystonia-parkinsonism   Not available
  Iranian family   p.R632W                    21, 22, and 25         Dystonia-parkinsonism   Not available

Key: NAD, neuroaxonal dystrophy.

[^1]: Equal contributions.
